# Twist Bioscience Startup profile on Capital Atlas: https://capitalatlas.ai/startups/twist-bioscience - Industry: Biotechnology - Headquarters: San Francisco, US - Website: www.twistbioscience.com - Total disclosed funding: $208M - Latest round: Series D (Dec 29, 2017) - Investors on record: 23 ## About Twist Bioscience Corp. specializes in DNA synthesis and biotechnology, providing innovative solutions for researchers across diverse scientific fields. Their technology enhances discoveries in areas such as precision medicine and genomic research.Twist Bioscience Corp. is focused on DNA synthesis and was founded in 2013 in San Francisco, US. The company has undergone significant growth, raising a total of USD 250.00 mn through various funding rounds, with the most recent being a Private Placement/Follow on raising USD 250.00 mn on June 3, 2020. Emily Leproust is the founder and current CEO, who has an extensive background in biotechnology.Twist Bioscience specializes in DNA synthesis and related biotechnological products that enable researchers to make advancements in scientific disciplines. The company offers highly customizable gene synthesis, targeted NGS solutions, and oligo pools for applications including CRISPR screening and liquid biopsy assays. Utilizing a proprietary semiconductor-based manufacturing process, they deliver high-throughput production and miniaturization, leading to efficiency gains. Their products are utilized by academic research institutions, pharmaceutical companies, and biotechnology firms primarily in North America, Europe, and Asia, supporting needs in precision medicine and infectious disease detection.In the most recent year, 2024, Twist Bioscience reported a revenue of USD 312,974. The company operates on a business-to-business model, selling products and solutions like Twist Genes, Twist Libraries, and Twist Oligo Pools to research clients. They also engage in partnerships with biopharmaceutical firms for customized service agreements, enhancing access to their offerings.Twist Bioscience aims to further its research and development in digital data storage in DNA following its latest funding round on February 22, 2022, where it raised USD 250.00 mn. The company is expected to introduce new product offerings and expand its market footprint, specifically targeting regions in North America and Europe by 2025. The previously raised capital will support these initiatives, contributing to advancements in their proprietary technologies. ## Funding rounds - Series D, Dec 29, 2017, $15M — Bay City Capital, Reinet Investments, Biomatics Capital Partners, 3W Partners, NFT Ventures, Ditch Plains Capital Management - Series D, Jun 14, 2017, $11M — Bay City Capital, Reinet Investments, FIS, Kangmei Pharmaceutical Co., Ltd, Biomatics Capital Partners, 3W Partners, NFT Ventures - Series D, May 18, 2017, $17M — Bay City Capital, Reinet Investments, Biomatics Capital Partners, 3W Partners, NFT Ventures, Ditch Plains Capital Management - Series D, Mar 9, 2017, $32M — Bay City Capital, Reinet Investments, Biomatics Capital Partners, 3W Partners, Ditch Plains Capital Management, NFT Investments PLC - Series D, Jan 8, 2016, $61M — ARCH Venture Partners, Paladin Capital Group, iGlobe Partners, Fidelity Investments, Merieux Equity Partners, Foresite Capital, Cormorant Asset Management, 6 Dimensions Capital, Tao Capital Partners, Illumina Ventures, ARCH Overage Fund - Series C, May 29, 2015, $37M — ARCH Venture Partners, Paladin Capital Group, Fidelity Investments, Foresite Capital, Tao Capital Partners, Illumina Ventures - Series B, May 13, 2014, $26M — ARCH Venture Partners, Paladin Capital Group, +ND Capital, Asset Management Ventures, Vital Venture Capital, Tao Capital Partners - Series A, Feb 7, 2014, $4.4M — ARCH Venture Partners, Paladin Capital Group - Series A, Jul 1, 2013, $4.8M — ARCH Venture Partners, Asset Management Ventures ## Investors - ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B, Series C, Series D - Asset Management Ventures (https://capitalatlas.ai/funds/asset-management-ventures) — Series A, Series B - Paladin Capital Group (https://capitalatlas.ai/funds/paladin-capital-group) — Series A, Series B, Series C, Series D - +ND Capital (https://capitalatlas.ai/funds/nd-capital) — Series B - Vital Venture Capital (https://capitalatlas.ai/funds/vital-venture-capital) — Series B - Tao Capital Partners (https://capitalatlas.ai/funds/tao-capital-partners) — Series B, Series C, Series D - Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C, Series D - Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C, Series D - Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series C, Series D - iGlobe Partners (https://capitalatlas.ai/funds/iglobe-partners) — Series D - Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Series D - Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series D - 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series D - ARCH Overage Fund — Series D - Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series D - Reinet Investments — Series D - Biomatics Capital Partners (https://capitalatlas.ai/funds/biomatics-capital-partners) — Series D - 3W Partners (https://capitalatlas.ai/funds/3w-partners) — Series D - Ditch Plains Capital Management — Series D - NFT Investments PLC — Series D - NFT Ventures (https://capitalatlas.ai/funds/nft-ventures) — Series D - FIS (https://capitalatlas.ai/funds/fis) — Series D - Kangmei Pharmaceutical Co., Ltd — Series D